Effects of atorvastatin on human C-reactive protein metabolism
Objective: Statins are known to reduce plasma C-reactive protein (CRP) concentrations. Our goal was to define the mechanisms by which CRP was reduced by maximal dose atorvastatin. Methods: Eight subjects with combined hyperlipidemia (5 men and 3 postmenopausal women) were enrolled in a randomized, p...
Saved in:
Main Authors: | , , , , , , |
---|---|
Other Authors: | |
Format: | Article |
Published: |
2018
|
Subjects: | |
Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/32556 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Mahidol University |
id |
th-mahidol.32556 |
---|---|
record_format |
dspace |
spelling |
th-mahidol.325562018-10-19T12:33:45Z Effects of atorvastatin on human C-reactive protein metabolism Nuntakorn Thongtang Margaret R. Diffenderfer Esther M.M. Ooi Bela F. Asztalos Gregory G. Dolnikowski Stefania Lamon-Fava Ernst J. Schaefer Tufts University Mahidol University University of Western Australia Faculty of Medicine and Dentistry Medicine Objective: Statins are known to reduce plasma C-reactive protein (CRP) concentrations. Our goal was to define the mechanisms by which CRP was reduced by maximal dose atorvastatin. Methods: Eight subjects with combined hyperlipidemia (5 men and 3 postmenopausal women) were enrolled in a randomized, placebo-controlled double-blind, cross over study. Subjects underwent a 15-h primed-constant infusion with deuterated leucine after 8 weeks of placebo and 80 mg/day of atorvastatin. CRP was isolated from lipoprotein deficient plasma, (density > 1.21 g/ml) by affinity chromatography. Isotopic enrichment was determined by gas chromatography/mass spectrometry. Kinetic parameters were determined using compartmental modeling. Paired t test and Wilcoxon signed ranks test were used to compare differences between placebo and atorvastatin. Results: Compared with placebo, atorvastatin decreased median CRP pool size by 28.4% (13.31 ± 3.78 vs 10.26 ± 3.93 mg; p = 0.16), associated with a median CRP fractional catabolic rate increase of 39.9% (0.34 ± 0.06 vs 0.50 ± 0.11 pools/day; p = 0.09), with no significant effect on median CRP production rate (0.050 ± 0.01 vs 0.049 ± 0.01 mg/kg/day; p = 0.78). Conclusion: Our data indicate that maximal doses of atorvastatin lower plasma CRP levels by substantially decreasing the median CRP plasma residence time from 2.94 days to 2.0 days, with no significant effect on the median CRP production rate. © 2012 Elsevier Ireland Ltd. 2018-10-19T05:33:45Z 2018-10-19T05:33:45Z 2013-02-01 Article Atherosclerosis. Vol.226, No.2 (2013), 466-470 10.1016/j.atherosclerosis.2012.11.012 18791484 00219150 2-s2.0-84872410105 https://repository.li.mahidol.ac.th/handle/123456789/32556 Mahidol University SCOPUS https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84872410105&origin=inward |
institution |
Mahidol University |
building |
Mahidol University Library |
continent |
Asia |
country |
Thailand Thailand |
content_provider |
Mahidol University Library |
collection |
Mahidol University Institutional Repository |
topic |
Medicine |
spellingShingle |
Medicine Nuntakorn Thongtang Margaret R. Diffenderfer Esther M.M. Ooi Bela F. Asztalos Gregory G. Dolnikowski Stefania Lamon-Fava Ernst J. Schaefer Effects of atorvastatin on human C-reactive protein metabolism |
description |
Objective: Statins are known to reduce plasma C-reactive protein (CRP) concentrations. Our goal was to define the mechanisms by which CRP was reduced by maximal dose atorvastatin. Methods: Eight subjects with combined hyperlipidemia (5 men and 3 postmenopausal women) were enrolled in a randomized, placebo-controlled double-blind, cross over study. Subjects underwent a 15-h primed-constant infusion with deuterated leucine after 8 weeks of placebo and 80 mg/day of atorvastatin. CRP was isolated from lipoprotein deficient plasma, (density > 1.21 g/ml) by affinity chromatography. Isotopic enrichment was determined by gas chromatography/mass spectrometry. Kinetic parameters were determined using compartmental modeling. Paired t test and Wilcoxon signed ranks test were used to compare differences between placebo and atorvastatin. Results: Compared with placebo, atorvastatin decreased median CRP pool size by 28.4% (13.31 ± 3.78 vs 10.26 ± 3.93 mg; p = 0.16), associated with a median CRP fractional catabolic rate increase of 39.9% (0.34 ± 0.06 vs 0.50 ± 0.11 pools/day; p = 0.09), with no significant effect on median CRP production rate (0.050 ± 0.01 vs 0.049 ± 0.01 mg/kg/day; p = 0.78). Conclusion: Our data indicate that maximal doses of atorvastatin lower plasma CRP levels by substantially decreasing the median CRP plasma residence time from 2.94 days to 2.0 days, with no significant effect on the median CRP production rate. © 2012 Elsevier Ireland Ltd. |
author2 |
Tufts University |
author_facet |
Tufts University Nuntakorn Thongtang Margaret R. Diffenderfer Esther M.M. Ooi Bela F. Asztalos Gregory G. Dolnikowski Stefania Lamon-Fava Ernst J. Schaefer |
format |
Article |
author |
Nuntakorn Thongtang Margaret R. Diffenderfer Esther M.M. Ooi Bela F. Asztalos Gregory G. Dolnikowski Stefania Lamon-Fava Ernst J. Schaefer |
author_sort |
Nuntakorn Thongtang |
title |
Effects of atorvastatin on human C-reactive protein metabolism |
title_short |
Effects of atorvastatin on human C-reactive protein metabolism |
title_full |
Effects of atorvastatin on human C-reactive protein metabolism |
title_fullStr |
Effects of atorvastatin on human C-reactive protein metabolism |
title_full_unstemmed |
Effects of atorvastatin on human C-reactive protein metabolism |
title_sort |
effects of atorvastatin on human c-reactive protein metabolism |
publishDate |
2018 |
url |
https://repository.li.mahidol.ac.th/handle/123456789/32556 |
_version_ |
1763488129659961344 |